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Abstracts
Mutations in pitrilysin metallopeptidase 1 (PITRM1), a mitochondrial protease involved in mitochondrial precursor
processing and degradation, result in a slow-progressing syndrome characterized by cerebellar ataxia, psychotic episodes,
and obsessive behavior, as well as cognitive decline. To investigate the pathogenetic mechanisms of mitochondrial
presequence processing, we employed cortical neurons and cerebral organoids generated from PITRM1-knockout human
induced pluripotent stem cells (iPSCs). PITRM1 deficiency strongly induced mitochondrial unfolded protein response
(UPRmt) and enhanced mitochondrial clearance in iPSC-derived neurons. Furthermore, we observed increased levels of
amyloid precursor protein and amyloid β in PITRM1-knockout neurons. However, neither cell death nor protein aggregates
were observed in 2D iPSC-derived cortical neuronal cultures. On the other hand, over time, cerebral organoids generated
from PITRM1-knockout iPSCs spontaneously developed pathological features of Alzheimer’s disease (AD), including the
accumulation of protein aggregates, tau pathology, and neuronal cell death. Single-cell RNA sequencing revealed a
perturbation of mitochondrial function in all cell types in PITRM1-knockout cerebral organoids, whereas immune
transcriptional signatures were substantially dysregulated in astrocytes. Importantly, we provide evidence of a protective role
of UPRmt and mitochondrial clearance against impaired mitochondrial presequence processing and proteotoxic stress. Here,
we propose a novel concept of PITRM1-linked neurological syndrome whereby defects of mitochondrial presequence
processing induce an early activation of UPRmt that, in turn, modulates cytosolic quality control pathways. Thus, our work
supports a mechanistic link between mitochondrial function and common neurodegenerative proteinopathies.
Introduction
Mitochondrial dysfunction has been described as a common
hallmark of neurological diseases [1]. However, in these
conditions, mitochondria are often considered a secondary
target rather than the actual disease driver. We have recently
described three independent families carrying missense loss
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of function mutations in pitrilysin metallopeptidase 1
(PITRM1), resulting in an age-dependent, progressive,
neurological syndrome [2, 3]. Patients suffer from pro-
gressive cerebellar dysfunction leading to cerebellar atro-
phy, with psychiatric manifestations including obsessive
behavior, anger attacks, and psychosis [2, 3]. Interestingly,
some of these patients showed a deterioration of their
cognitive functions with a slow progression until their late
sixties [2, 3]. Human PITRM1, also known as presequence
peptidase (hPreP), is a nuclear-encoded mitochondrial gene
expressed in a number of tissues, including muscles and
different brain regions, e.g., the cortex, hippocampus, cer-
ebellum, and tectum [4]. PITRM1 was initially identified in
Arabidopsis thaliana as a protease that degrades targeting
peptides in mitochondria and chloroplasts [5]. Human
PITRM1 is a mitochondrial matrix enzyme that digests the
mitochondrial-targeting sequences (MTS) of proteins
imported across the inner mitochondrial membrane after
their cleavage from protein precursors by the mitochondrial
matrix presequence peptidase (MPP). When the MTS are
not properly degraded, they accumulate within the mito-
chondrial matrix, causing dissipation of the mitochondrial
membrane potential and mitochondrial dysfunction [6–8].
The incomplete processing of mitochondrial preproteins
leads to their destabilization, resulting in alterations of
mitochondrial proteostasis [9]. In vitro studies using
recombinant PITRM1 have shown that, besides MTS, the
enzyme is also involved in the degradation of short,
unstructured peptides, and amyloid beta (Aβ) peptides
[9–12]. Interestingly, Aβ peptides inhibit the activity of
CYM1, the PITRM1 orthologue in yeast, leading to the
accumulation of precursor proteins [9]. Experimental work
in mouse models supports a causal role of PITRM1 in
neurodegenerative dementia, whereby the loss of PITRM1
function leads to a progressive, neurodegenerative pheno-
type characterized by hindlimb clasping, impairment in
motor coordination, and basal-ganglia-related movement
control [2]. Interestingly, PITRM1-deficient mice exhibit an
age-dependent accumulation of amyloid precursor protein
(APP) and Aβ deposits within the brain [2], suggesting a
link between defects of mitochondrial proteostasis and
adult-onset neurodegenerative dementia. However, due to
the embryonic lethality observed in complete PITRM1-
knockout mice, the exact role of PITRM1 in brain home-
ostasis and disease could not be studied [2]. Because
PITRM1 is involved in the degradation of MTS, as well as
Aβ peptides [9], the pathomechanisms of neurodegeneration
linked to the loss of PITRM1 function could, in principle,
be due to either an accumulation of Aβ peptides in mito-
chondria, MTS-driven toxicity, or a combination of both.
Identifying the mechanisms that lead to neurodegeneration
in primary mitochondrial diseases characterized by defects
of mitochondrial proteostasis, such as PITRM1-linked
neurological syndrome, may help clarify the long-debated
but still unresolved involvement of altered mitochondrial
function in neurodegenerative dementia. To examine
PITRM1-related pathogenetic mechanisms, we generated
PITRM1-knockout human induced pluripotent stem cells
(iPSCs) and examined the role of mitochondrial function
and proteostasis using 2D neuronal and 3D brain-organoid
model systems.
Methods
Generation of PITRM1-knockout human iPSCs
The control iPSCs (from a female non-affected control
donor, 80 years) used in this study were previously gener-
ated and characterized [13]. All cells used in the study were
derived from patients who had signed an informed consent
approved by the Ethics Committee of the Medical Faculty
and the University Hospital Tübingen. iPSCs were kept in
culture in hESC medium [13]. SgRNAs targeting exon 3
and exon 4 of the PITRM1 gene were designed using
CRISPR Guide Design Tools (former www.crispr.mit.edu)
and purchased from Metabion International AG (exon 3 top
AGGAGCCAGGTATTTACACC, exon 3 bottom GGTGT
AAATACCTGGCTCCT, exon 4 top TTGAGCATACCGT
CCTTTGT, exon 4 bottom ACAAAGGACGGTATGCT
CAA). SgRNAs were cloned into the pSpCas9(BB)-2A-
Puro plasmid containing the sgRNA scaffold and
puromycine-resistance under the U6 promoter (Addgene
plasmid #48139). Colonies that successfully integrated
sgRNA into the backbone plasmid were screened and
confirmed by Sanger sequencing using the U6 promoter
region primer. SgRNA/Cas9 plasmid was delivered into
cells using the Nucleofector Amaxa system (Lonza Bios-
ciences, NC, USA). In brief, iPS cells were dissociated with
Accutase (Sigma-Aldrich, MO, USA) and 106 iPSCs were
nucleofected with 6 µg of each sgRNA plasmid. The cells
were then replated on MEF cells in hESC medium, without
P/S, supplemented with 10 µM ROCK Inhibitor Y-27632 2
HCl. After recovery, cells were replated at a density of 500
cells/cm2 for single-cell subcloning. After recovery, iPSCs
were clonally expanded and the genomic deletion was
assessed by PCR and Sanger sequencing (exon 3 Fw
TTCAGGCAGAAAAGCCAGTT, exon 4 Rv ACTGAATT
CCAGTGGGTGTGC). The analysis of possible off-target
effects was performed using CRISPR Design Tools.
Sequencing primers for off-target effects: (5′–3′): PPIL2
NM_148175 Fw CCTCATGCCCTGCTTGACTC, Rv
CAGGGAGCACTGTCCCAATTT; NR1D1 NM_021724
Fw CAAACGAGCACACACCACAG, Rv GCTGCCCCC
TTGTACAGAAT; KDEL2 NM_001100603 Fw TTGGT
GGTGGTTATGCCTCA, Rv ACCACCAGAAACTCCAC
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TCG; FAM120A NM_014612Fw TCCTGCGGTTCTT
GTCCTCTA, Rv GCATGAATGTGTCTTCTCTGGC; TT
LL2 NM_031949 Fw GTGGGAGGCTGTGTGGTATT,
Rv TCAAGTCCCTACCTGTGCCA; SUCO NM_014283
Fw AATCTGGTACTATTCCGATAGCCAA, Rv CCATT
CAAACAGGACACTGCTG.
Cortical neuronal differentiation
For the induction of cortical neurons, we used an embryoid
body (EB)-based differentiation protocol, with minor mod-
ifications [14]. iPSC colonies were manually chosen and
grown for 4 d in EB media (20% KO serum replacement in
DMEM/F12 medium, 1% NEAA, 1% P/S). On day 5, EBs
were plated onto a Matrigel-coated (Corning, NY, USA)
plate and grown for 4 more days in N2B27 media (DMEM/
F12, 1× N2, 1× B27-RA, 1% NEAA, 1% P/S, 20 ng/mL
bFGF). For the first 8 differentiation days, the cells were
grown in the presence of 10 μM SB431542 (Ascent Scien-
tific, UK) and 2.5 μM dorsomorphin (Sigma-Aldrich, MO,
USA). After 8 days, neural rosettes were lifted with dispase,
replated onto a matrigel-coated plate, and grown in N2B27
media. Secondary or tertiary rosettes were manually dis-
sected to purify neural progenitor cells (NPCs). For cortical
differentiation, NPCs were dissociated with Accutase and
seeded at a density of 1000 cells per mm2 on matrigel-coated
plates in a neuronal differentiation medium consisting of
DMEM/F12,1× Glutamax, 1× N2, 1× B27-RA, 20 ng/mL
BDNF (Peprotech, NJ, USA), 20 ng/mL GDNF, 1 mM
dibutyryl-cyclic AMP (Sigma-Aldrich, MO, USA), and
200 nM ascorbic acid (Sigma-Aldrich, MO, USA). The
medium was replaced every other day.
Cerebral organoids culture and
immunohistochemistry
Cerebral organoids were generated and maintained using
the protocol described by Lancaster et al. [15]. Where
indicated, cerebral organoids were treated with 500 nM
ISRIB or 500 μM nicotinamide mononucleotide (NMN)
(both from Sigma-Aldrich, MO, USA) daily, from DIV 20
to DIV 50 or from DIV 45 to DIV 50, respectively. For
immunostaining, organoids were washed with PBS, fixed
in 4% PFA for 15 min and then equilibrated in 30% sucrose
in PBS overnight at 4 °C. The next day, the organoids were
embedded in blocks with a mixture of 10% sucrose/7.5%
gelatin, snap-frozen, and kept at −80 °C until cryosections
were prepared using a Leica CM 1900 instrument (Leica,
Germany) with a 20-μm thickness. Sections were then
permeabilized and blocked with 10% normal goat serum in
PBS in 0.5% Triton X-100. Primary antibody incubations
were performed at 4 °C overnight, followed by three 10-
min washes in PBS and staining with Alexa Fluor
secondary antibodies (1:1000, Invitrogen, MA, USA) at the
room temperature for 1 h. Primary antibodies included rat
anti-CTIP2 (1:500, Abcam #ab18465, UK), rabbit anti-
TBR1 (1:500, Abcam ab31940, UK), mouse anti-β-III-
tubulin (1:1000, BioLegend, CA, USA. Previously
Covance #PRB-435P), chicken anti-MAP2 (1:3000, Bio-
Legend #PCK-554P, CA, USA), mouse anti phospho-tau
AT8 (Ser202, Thr205) (1:1000, Invitrogen #MN1020, MA,
USA), mouse anti-APP (1:500, Santa Cruz Biotechnology
#sc53822, TX, USA), mouse anti-ubiquitin (1:100, Merck
#MAB1510, NJ, USA), rabbit anti-cleaved caspase-3
(1:500, Cell Signaling Technology #9664T, MA, USA),
and Phalloidin-iFluor 594 Reagent (1:1000, Abcam
#ab176757, UK). Sections were stained with 10 μM
thioflavin-T (Sigma-Aldrich #T3516, MO, USA) or 10 μM
BTA-1 (Sigma-Aldrich #B9934, MO, USA) for 30 min at
the room temperature and washed three times in PBS.
Images were acquired using a Leica TCS SP8 confocal
microscope (Leica, Germany) equipped with a 63 × /1.4
numerical aperture oil-immersion objective. For each con-
dition, 10–15 images were acquired from at least five
organoids from three independent experiments (cultures).
For quantification of tau/p-tau, APP, and ubiquitin immu-
noreactivity, the mean fluorescence intensity of the whole
field was measured using Image J. Quantification of
cleaved caspase-3-positive neurons was performed using
Fiji distribution of ImageJ from confocal z-stacks (the
number of cleaved caspase-3-positive cell was normalized
on total number of β-TUBIII/DAPI positive cells from the
whole field). For analyses of amyloid-like plaque size,
the measurement of the particle area was performed using
the ImageJ “threshold/analyze particle” plugin.
Calcium imaging
For cytosolic calcium imaging, neurons were loaded with 1
μM Fluo-4-AM (Invitrogen, MA, USA) for 30 min at 37 °C.
After loading, cells were washed twice with Krebs-Ringer-
HEPES (20 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM
MgSO4,1 mM CaCl2, and 5.5 mM glucose, pH 7.4) (KRH)
buffer and imaged using a Leica TCS SP8 confocal
microscope (Leica, Germany) equipped with a 63 × /1.4
numerical aperture oil-immersion objective. After 1 min of
equilibration time (baseline), neurons were exposed to
0.6 mM KCl. Fluo-4 AM was excited at 488 nm and the
emission was collected at 510 nm. Images were captured
every 25 s. All images were processed using Image J soft-
ware. Data were normalized to the baseline.
Measurement of mitochondrial membrane potential
For measurement of the mitochondrial membrane poten-
tial, iPSC-derived neurons were incubated with 100 nM
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Tetramethylrhodamine Methylester Perchlorate (TMRM)
and 100 nM MitoTracker Green (both from Invitrogen,
MA, USA) in a KRH buffer for 30 min at 37 °C and then
imaged using a Leica TCS SP8 confocal microscope
(Leica, Germany) with a 63 × /1.4 numerical aperture oil-
immersion objective. The 568 nm laser line was used to
excite TMRM and the 488 nm laser line to excite Mito-
Tracker Green. Emitted fluorescence was measured above
574 nm for TMRM and between 490 and 530 nm for
MitoTracker Green. Z-stacks were acquired for calcula-
tions of the mitochondrial membrane potential. Image J
was used to quantify TMRM intensity in individual
MitoTracker-Green-positive mitochondria. Basal TMRM
levels were taken as 100% and the remaining TMRM
fluorescence in the mitochondria after complete depolar-
ization by FCCP was regarded as background. Intensities
were corrected for background subtraction. Data were
obtained from n > 40 cells from three independent
experiments.
Measurement of mitochondrial reactive oxygen
species (mtROS)
For the measurement of mtROS production of iPSC-derived
neurons by flow cytometry, cells were preincubated with N2
medium for 48 h. Then, 1 × 106 cells were washed once
with HBSS, incubated with 5 µM of the superoxide indi-
cator MitoSOX Red (Invitrogen, MA, USA) for 30 min at
37 °C, washed twice with HBSS, dissociated using trypsin
(Invitrogen, MA, USA), and resuspended in 200 μL of
HBSS and 1% BSA. The cytofluorimetric analysis was
performed using MACSQuant Analyzer 10 (Miltenyi Bio-
tec, Germany).
Seahorse XFp metabolic flux analysis
The oxygen consumption rate was analyzed using an XFp
Extracellular Flux Analyzer (Agilent, CA, USA). iPSC-
derived neurons were plated on XFp microplates (Agilent,
CA, USA) at a density of 70,000 per well and grown in N2
medium for 48 h before the experiment. Measurement of the
neuronal oxidative consumption rate was performed in a
freshly prepared medium consisting of phenol-free DMEM,
1 mM sodium pyruvate, 2 mM glutamine, and 10 mM glu-
cose with the pH adjusted to 7.4. Mitochondrial function
was evaluated at baseline levels and after the subsequent
injection of 10 μM oligomycin, 10 μM carbonyl cyanide p-
trifluoromethoxyphenylhydrazone, and 1 µM antimycin A/
1 µM rotenone (all Sigma-Aldrich, MO, USA). Three
measurements, lasting 5 min each, were taken for each
condition. The measured values were normalized on protein
concentration measured by BCA.
Quantitative RT-PCR
mRNA was isolated using an RNA isolation kit (Qiagen,
Germany). Following the reverse transcription reaction
using the QuantiTect Reverse Transcription Kit, a quanti-
tative PCR reaction was performed using SYBR Green (all
Qiagen, Germany) and monitored with a Viia7 Real-Time
PCR system (Applied Biosystems, CA, USA). The
expression level of each gene was normalized to the
housekeeping gene ribosomal protein large P0 (Rplp0).
Fold changes in gene expression were calculated using the
2−DDCT method, based on biological reference samples and
housekeeping genes for normalization.
qPCR primers (5′–3′)
GAPDH Fw AGGGGAGATTCAGTCTGG
Rv CGACCACTTTGTCAAGCT
HSP60 Fw TGACCCAACAAAGGTTGTGA
Rv CATACCACCTCCCATTCCAC
LONP1 Fw CCCGCGCTTTATCAAGATT
Rv AGAAAGACGCCGACATAAGG
ATF4 Fw GTCCCTCCAACAACAGCAAG
Rv CTATACCCAACAGGGCATCC
DDIT3 Fw AGCCAAAATCAGAGCTGGAA
Rv TGGATCAGTCTGGAAAAGCA
ERO1A Fw AGCGGCACAGAGGTGCT
Rv TGTAGTCTTGGGAAAAGCCTG
RPLP0 Fw CCTCATATCCGGGGGAATGTG
Rv GCAGCAGCTGGCACCTTATTG
HSPA9 Fw GGAAGCTGCTGAAAAGGCTA
Rv CTTGGGTCCAGAAGAATCCA
CLPP Fw CTCTTCCTGCAATCCGAGAG
Rv GGATGTACTGCATCGTGTCG
16S (mtDNA) Fw GCCTTC CCCCGTAAATGATA
Rv TTATGCGATTACCGGGCTCT
PITRM1 Fw ATCTGTTCCCGAGCTGTTCC
Rv GAAAGGCTCTCTGCACGGAT
APP Fw TGGAGGTACCCACTGATGGT
Rv TTGTCAGGAACGAGAAGGGC
Mitochondrial isolation
Mitochondrial isolation was performed using a Qproteome®
Mitochondria Isolation Kit (Qiagen, Germany) according to
the manufacturer’s protocol.
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Western blot
Proteins were extracted using tris-buffered Saline (TBS)
with a 0.5% NP40 protein extraction buffer containing
protease and phosphatase inhibitors (Roche, Switzerland),
on ice, following centrifugation at 14,000 rpm and 4 °C for
15 min. The protein concentration of the supernatant was
determined by BCA (Pierce, WI, USA). In total, 15–30 μg of
the protein lysate was loaded on polyacrylamide gel (the
density ranged from 7.5 to 15%, depending on the respective
protein molecular weight) and transferred on a PVDF
membrane (Millipore, MA, USA). Blots were blocked with
5% milk powder or 5% BSA in TBS+ 0.1% Tween-20
(TBST) and incubated with primary antibodies in milk or
BSA blocking solution overnight at 4 °C. This step was
followed by incubation with corresponding HRP-conjugated
secondary antibodies (Sigma-Aldrich, MO, USA) for 1 h at
the room temperature. Visualization of proteins was carried
out using Amersham ECL Western Blotting Detection
Reagent and Amersham Hyperfilm (both GE Healthcare, IL,
USA). Densitometric analysis of proteins was performed by
ImageJ software. Primary antibodies included rabbit anti-
LC3B (1:500, Cell Signaling Technologies #2775, MA,
USA), mouse anti-APP 6E10 (Abeta 1-16) (1:1000, Bio-
Legend #803004, CA, USA), rabbit anti-PITRM1 (1:1000,
Atlas Antibodies #HPA006753, Sweden), rabbit anti-
Frataxin (1:1000, Abcam #ab175402, UK), mouse total
OXPHOS human WB antibody cocktail (1:1000, Abcam
#ab110411, UK), mouse anti-ubiquitin (1:5000, Millipore
#MAB1510, MA, USA), mouse anti-HSPA9/GRP 75
(1:3000, Santa Cruz Biotechnology #sc-133137, TX, USA),
mouse anti-HSP60 (1:3000, Santa Cruz Biotechnology #sc-
271215, TX, USA), rabbit anti-LONP1 (1:3000, Proteintech
#15440-1-AP, IL, USA), mouse anti-tau (1:1000, HT7,
Thermo Fisher Scientific #MN1000, MA, USA), mouse anti
phospho-tau PHF-6 (Thr231) (1:1000, Thermo Fisher Sci-
entific #35-5200, MA, USA), mouse anti phospho-tau AT8
(Ser202, Thr205) (1:1000, Thermo Fisher Scientific
#MN1020, MA, USA), mouse anti phospho-tau Thr181
(1:1000, Thermo Fisher Scientific #MN1050, MA, USA),
mouse anti-β-Actin (1:20000, Sigma-Aldrich #A5441, MO,
USA), and mouse anti-VDAC1 (1:1000, Santa Cruz Bio-
technology #sc-390996, TX, USA).
Autophagy studies
Where indicated, cells were treated with NH4Cl (20 mM)
and leupeptin (200 μM) (EMD, Millipore, MA, USA) for
4 h. Light chain type 3 protein (LC3-II) and LC-I levels
were quantified by densitometry and normalized to β-actin.
LC3 flux was quantified by dividing the levels of LC3-II
after treatment with lysosomal inhibitor for 4 h by the levels
of LC3-II without treatment.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde (PFA) in PBS
(w/v) for 10 min, rinsed with PBS, and blocked by 10%
normal goat or donkey serum (NGS/NDS) in PBST (PBS+
0.1% Triton X-100) for 60 min. Cells were then incubated
with primary antibodies in 10% NGS/NDS in PBST over-
night at 4 °C following 1 h of incubation at 24 °C with the
appropriate Alexa 488/568 coupled secondary antibodies
(1:1000, Invitrogen, MA, USA). Cell nuclei were stained
with DAPI; final images were acquired using a Leica TCS
SP8 confocal microscope (Leica, Germany) and analyzed
using Fiji software. Primary antibodies included rabbit anti-
LC3B (1:500, Cell Signaling Technologies #2775, MA,
USA), rabbit anti-TBR1 (1:500, Abcam #ab31940, UK),
and mouse anti-β-III-tubulin (1:1000, BioLegend, CA,
USA. Previously Covance PRB-435P). For live imaging of
Aβ in neuronal cultures, cells were incubated with 100 nM
BTA-1 and 1 μM NeuroFluor™ NeuO (Invitrogen, MA,
USA) for 20 min. The LC3 particle number in β-III-tubulin-
positive cells was quantified with the “analyse particles”
plug-in in ImageJ (NIH). Quantification was carried out on
at least 50 cells per condition, from three independent
experiments.
LDH assay
The LDH assay (Promega, WI, USA) was performed as per
the manufacturer’s instructions.
Amyloid β species measurement
For amyloid β species measurement in iPSC-cortical neu-
rons, 106 cells were plated into one well of a 12-well plate;
cell supernatant was collected after 5 days, snap-frozen, and
stored at −80 °C until analysis. A cell pellet was collected
and lysed to determine the protein concentration and used
for value normalization. Conditioned medium from at least
three technical replicates was collected in each experiment.
For amyloid β species measurement in cerebral organoids,
individual organoids were replated into low-attachment 96-
well plates on an orbital shaker. Supernatant was collected
after 5 days, snap-frozen in liquid nitrogen, and stored at
−80 °C until analysis. After the collection of the super-
natant, individual organoids were lysed and the protein
concentration was measured with BCA for value normal-
ization. The concentrations of Aβ40 (Aβx–40) and Aβ42
(Aβx–42) in the samples were measured on a Sector Imager
6000 using an electro chemiluminescence-based immu-
noassay, V-PLEX Aβ Peptide Panel 1 (6E10) Kits (Meso
Scale Discovery, MD, USA) according to the manu-
facturer’s instructions. All samples were thawed on ice and
diluted 1:2 in a buffer (Diluent 35, Meso Scale Discovery,
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer’s. . .
MD, USA) before incubation. A neural differentiation
medium without B27/N2 supplements was used as the
negative control for each measurement. Human CSF sam-
ples were used as internal references on each plate. At least
eight organoids were used for each measurement. Every
sample was tested in duplicate (and excluded if the coeffi-
cient of variance was above 20%). Data analysis was run
using the MSD DISCOVERY WORKBENCH software,
version 2.0.
ELISA
Individual cerebral organoids were homogenized in an ice-
cold RIPA buffer containing protease and phosphatase
inhibitors (Roche, Switzerland), following centrifugation at
14,000 rpm and 4 °C for 10 min. The protein concentration
of the supernatant was determined by BCA (Pierce, WI,
USA). Total and phospho-tau levels, as well as IL-1β and
TNF-α levels, were assessed, in equal protein amounts,
using ELISA assay kits (total-tau #KHB0041 and phosho-
tau #KHO0631, both Invitrogen (MA, USA); IL-1β
#DY201 and TNF-α #DY210, both DuoSet ELISA, R&D
Systems, MN, USA), according to the manufacturer’s
instructions.
10X Genomics single-cell RNA sequencing
Cerebral organoids were dissociated into a single-cell
suspension using a Worthington Papain Dissociation Sys-
tem kit (Worthington Biochemical, OH, USA), as per the
manufacturer’s instructions. Cerebral organoids were
minced and incubated with a 2.5 Papain/DNAase solution
on an orbital shaker for 1 h at 37 °C. Organoid suspensions
were intermittently triturated (30 times every 30 min) using
1 ml low-attachment pipette tips. Cell suspensions under-
went several filtering (40, 30 μm) and washing steps with
HBSS. The final solution was centrifuged 300 g per 7 min
and the cell pellet was resuspended in PBS-0.5% BSA and
filtered using a 30 μm strainer. The final preparation con-
tained over 95% live-cells at a concentration of 1000 cells/
μL. Single-cell suspension concentration and cell viability
were determined by microscopy using trypan blue staining
(0.2%) and by automatic cell counting (DeNovix CellDrop,
DE, USA) using an AO/PI viability assay (DeNovix, DE,
USA). scRNA-seq libraries were generated using the 10X
Chromium Next gel beads-in-emulsion (GEM) Single Cell
3’ Reagent Kit v3.1 according to the manufacturer’s
instructions. Approximately 18,000 cells per sample were
loaded on the Chromium Next GEM Chip G, which was
subsequently run on the Chromium Controller (10X
Genomics, CA, USA) to partition cells into GEMs. Cell
lysis and reverse transcription of poly-adenylated mRNA
occurred within the GEMs and resulted in cDNA with
GEM-specific barcodes and transcript-specific unique
molecular identifiers (UMIs). After the breaking of the
emulsion, cDNA was amplified (11 cycles), enzymatically
fragmented, end-repaired, extended with 3′ A-overhangs,
and ligated to adapters. P5 and P7 sequences, as well as
sample indices (Chromium i7 Multiplex kit, 10X Geno-
mics, CA, USA), were added during the final PCR ampli-
fication step. The fragment size of the final libraries was
determined using the Bioanalyzer High-Sensitivity DNA
Kit (Agilent, CA, USA). Their concentration was deter-
mined using the Qubit dsDNA HS Assay Kit (Thermo
Fisher Scientific, MA, USA). scRNA libraries were pooled
and paired-end-sequenced on the Illumina NovaSeq 6000
platform.
Single-cell sequencing data analysis
Samples were demultiplexed and the 10X Genomics pipe-
line cellranger count was run to generate filtered gene-
barcode matrices (the number of UMIs associated with a
gene and a cellular barcode). Filtered gene-barcode matrices
were used as input for downstream analysis using the R
package Seurat [16, 17]. Seurat objects were merged and
potential low-quality cells (UMI < 2500, detected genes
<500) and cells with UMI counts over 15,000 were
removed. Each dataset was normalized by dividing the gene
count for each cell by the total counts of that cell. The
results were multiplied by 10,000 (scale factor), natural-log-
transformed, and used as input to determine the cell cycle
scores (Seurat CellCycleScoring) for each cell and to
visualize gene expression of the marker gene. Subsequently,
each dataset was SCtransform normalized and prepared for
sample integration by performing canonical correlation
analysis to identify the greatest sources of variation con-
served across all samples, followed by anchor identification
and filtering. After integration of the samples, principle
components (PCs) were determined and, using the first 40
PCs, cells were clustered using a K-nearest neighbor graph
with a clustering resolution of 0.8, resulting in 26 clusters.
Cell clusters were visualized using UMAP. Conserved
markers were determined across all samples for each cluster
(FindConservedMarkersfunction) using the default settings
(min.pct=0.25, logfc.threshold=0.25) and used for assign-
ing the cell type to cell clusters. Differently expressed genes
between conditions in each cluster were determined using
the FindMarkers function with the Wilcoxon Rank Sum test
(min.pct=0.1, logfc.threshold=0.1) and p value adjustment
by Bonferroni correction based on the total number of genes
in the dataset. Pathway analysis of differentially expressed
genes (DEGs) was performed using Ingenuity pathway
analysis (IPA© 2000–2020, Ingenuity® Systems, www.
ingenuity.com). scRNA-seq data are available at NCBI
GEO (GEO accession number GSE147047).
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Statistical analysis
The Statistical Package GraphPad Prism versions 7 and 8.3
(GraphPad Software) was used to analyze the data. Statis-
tical significance was evaluated using a two-tailed Student’s
t test. Data are expressed as mean+ S.E.M.
Results
Mitochondrial dysfunction in PITRM1-knockout
iPSC-derived neurons
To overcome the limitation of the embryonic lethality pre-
viously observed in PITRM1-knockout mice [2] and
examine the mechanistic link between PITRM1 deficiency
and neurodegeneration in a model that more closely
resembles human disease, we generated PITRM1-
knockout (PITRM1−/−) human iPSCs using CRISPR/Cas9
endonuclease-mediated gene editing. Appropriate sgRNAs
targeting exon 3 and exon 4 were designed to introduce a
frameshift deletion resulting in the complete knockout of
the PITRM1 protein (Supplementary Fig. 1a). Several
homozygous clones were generated and two fully char-
acterized clones were selected and used for further analysis
(Supplementary Fig. 1b–e). To address the impact of
PITRM1 on the function of human neurons, we differ-
entiated PITRM1+/+ and PITRM1−/− iPSCs into neuronal
cultures that were enriched for cortical neurons; we assessed
the neuronal cultures at 35 and 65 days in vitro (DIV).
Western blot analysis confirmed the complete absence of
PITRM1 protein in differentiated PITRM1−/− iPSCs (Sup-
plementary Fig. 1d, e). Both PITRM1+/+ and PITRM1−/−
iPSCs efficiently generated cortical neurons without sig-
nificant differences (Fig. 1a, b). Furthermore, PITRM1+/+
and PITRM1−/− showed a similar increase in cytosolic
calcium after KCl stimulation (Supplementary Fig. 1f, g).
No overt cell death was observed in neuronal cultures, as
assessed by LDH assay at 35 and 65 DIV (Supplementary
Fig. 1h). Previous work showed that PITRM1 deficiency
leads to the accumulation of non-degraded MTS sequences
that, in turn, impair the processing of presequence proteins
by the peptidase MPP [9]. Because mitochondrial pepti-
dases are also involved in the maturation of the human
frataxin precursor [18, 19], we examined frataxin matura-
tion by immunoblotting. A decreased ratio of processed,
mature to immature frataxin was detected in PITRM1−/−
iPSC-derived NPCs and neurons (Supplementary Fig. 1i, j),
indicating the impaired function of MPP and defects of
mitochondrial presequence processing. Because MTS pep-
tides can bind to the membrane and perturb the mitochon-
drial electrochemical gradient, we evaluated the effect of
PITRM1 deficiency on mitochondrial membrane potential
and respiratory oxidative activity. Mitochondrial membrane
potential was reduced in PITRM1−/− neurons compared
with isogenic PITRM1+/+neurons (Fig. 1c, d). Interestingly,
this decrease was more evident in neurites than in soma
(Fig. 1c, d). However, mtROS were not significantly altered
in PITRM1−/− neurons (Supplementary Fig. 2a). Similarly,
no significant difference in respiratory oxidative activity
was observed between PITRM1+/+ and PITRM1−/− neu-
rons (Supplementary Fig. 2b). Western blot analysis
revealed a significant increase in the level of Complex II
respiratory chain complex subunits in PITRM1−/− neurons
(Supplementary Fig. 2c, d). However, no significant dif-
ference for the levels of all other respiratory chain complex
subunits was detected in PITRM1−/− neurons (Supple-
mentary Fig. 2c, d).
PITRM1−/− iPSC-derived cortical neurons show the
induction of mitochondrial stress response and
enhanced mitophagy
Mitochondrial stress response has been identified as a
common signature in several neurodegenerative as well as
primary mitochondrial diseases [20–23]. Thus, we exam-
ined the expression levels of genes involved in mitochon-
drial unfolded protein response (UPRmt) and, more
generally, in the mitochondrial integrated stress response
pathway (mtISR). PITRM1−/− iPSC-derived cortical neu-
rons exhibited a significant induction of UPRmt/mtISR
transcripts (ATF4, DDIT3, HSP60, HSPA9, ERO1)
(Fig. 1e). Moreover, gene expression of the mitochondrial
proteases, LONP1 and CLPP, was significantly upregulated
in PITRM1−/− neurons as compared with the controls
(Fig. 1e). In line with the gene expression data, we found an
increase in the protein expression of the chaperones HSPA9
and HSP60 and the mitochondrial protease LONP1 (Fig. 1f,
g). These data suggest that PITRM1 deficiency leads to a
strong upregulation of the ISR pathway. Because the ISR
has been shown to activate autophagy [24, 25], we assessed
the autophagosome content by immunostaining for endo-
genous LC3, a marker of autophagosomes. Our analysis
revealed a significant decrease of LC3-positive vesicles in
PITRM1−/− neurons compared with isogenic PITRM1+/+
neurons (Supplementary Fig. 2e, f). These results were
confirmed by western blot, showing decreased basal levels
of LC3-II in PITRM1−/− neurons (Fig. 1h). However,
inhibition of lysosomal degradation by leupeptin and
ammonium chloride revealed that the autophagic flux was
significantly increased in PITRM1−/− neurons, thus con-
firming autophagy activation (Fig. 1h, i). To assess whether
the observed increase in autophagic flux leads to an
enhanced turnover rate of mitochondria by autophagy, we
purified mitochondria from PITRM1+/+ and PITRM1−/−
iPSC-derived cortical neurons. Immunoblotting of purified
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mitochondria showed increased ubiquitination of
PITRM1−/− neurons as compared with PITRM1+/+ neurons
(Fig. 1j, k), suggesting their targeting to lysosomes and
increased mitochondrial clearance [26]. In line with these
results, mitochondrial content was lower in PITRM1−/−
neurons, as shown by a reduced mitochondrial-to-nuclear-
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DNA ratio (Fig. 1l). Taken together, these results suggest
that the loss of PITRM1 function enhances mitochondrial
clearance.
PITRM1−/− iPSC-derived neurons show the
accumulation of APP and an increase in extracellular
Aβ peptides levels
To examine the impact of PITRM1 activity on Aβ pathol-
ogy, we first assessed the levels of APP by western blot.
APP protein levels were found to be significantly increased
in PITRM1−/− neurons as compared with PITRM1+/+
neurons (Fig. 2a, b). Next, supernatant from PITRM1+/+
and PITRM1−/− cortical neurons was analyzed using the
MesoScale Discovery immunoassay for human Aβ pep-
tides. PITRM1−/− neurons showed significantly higher
levels of Aβ40 and Aβ42 peptides as well as an increased
Aβ42/Aβ40 ratio compared with control samples (Fig. 2c).
Remarkably, Aβ peptides were not detected in mitochon-
drial extracts from PITRM1-deficient neurons. Next, we
explored the mechanisms that link the loss of PITRM1
function with the alteration of APP metabolism. We found a
significant decrease of APP mRNA levels in PITRM1−/−
neurons (Fig. 2d). Because UPRmt may have an impact on
ubiquitin-dependent protein turnover [27], we examined the
levels of ubiquitinated proteins by western blot. We
observed that PITRM1−/− display increased levels of ubi-
quitinated proteins (Fig. 2e, f), suggesting defects in cellular
proteostasis. Despite APP accumulation and an increased
Aβ42/Aβ40 ratio, 2D iPSC-derived neuronal cultures did
not show Aβ aggregates (Supplementary Fig. 2g). We
found an increase in both phosphorylated tau (pThr231,
pSer202+ Thr205, and pThr181) and total tau in
PITRM1−/− neurons (Supplementary Fig. 2h). However,
the p-tau/total tau ratio was not significantly altered (Sup-
plementary Fig. 2h, i).
scRNA-seq of PITRM1−/− cerebral organoids reveals
a cell-type-specific impact
To further investigate the mechanisms of PITRM1 neuro-
toxicity in a model that better resembles the human disease,
we developed cerebral organoids from PITRM1+/+ and
PITRM1−/− iPSCs and cultured them over a broad time
span (1–6 months). Cerebral organoids derived from
PITRM1+/+ and PITRM1−/− iPSCs displayed similar sizes
and cortical layering characteristics (Fig. 3a and Supple-
mentary Fig. 3a). To comprehensively characterize the cell
types present in cerebral organoids and gain insight into
cell-type-specific mechanisms, we transcriptionally profiled
2-month-old cerebral organoids using 10X Genomics
Chromium Single Cell RNA Sequencing. Using an unsu-
pervised cell-clustering algorithm, we identified 26 separate
cell clusters. Individual clusters contained between 32 and
1712 cells and were defined by the first 40 principal com-
ponents (Fig. 3b). For specific gene expression compar-
isons, these clusters were manually assigned based on the
expression of known cell-type-specific markers (Fig. 3c,
Supplementary Fig. 3b, c and Supplementary Table 1)
to progenitor cells, including NPC (TOP2A, MKI67,
CENPF, UBE2C) and radial glia (SLC1A3, SOX2, GLI3,
HES1, PAX6, SOX9) (clusters 4, 6, 10, 16, and 24), neurons
(STMN2, DCX, RELN, NEUROD2, NEUROD6) (clusters 0,
1, 2, 5, 7, 8, 12, 14, 15, 17, 18, 19, 20, and 21), astrocytes
(GJA1, S100B) (clusters 9 and 13), microglia (TMEM119,
OLFML3) (clusters 22 and 25), and additional glial cell
types not contained in these groups (CRYAB, OLIG1,
APOE, HLA-B, CEBPB) (clusters 3, 11, and 23) (Fig. 3c, d).
Among the neuronal clusters, we further identified layer I
cortical neurons (clusters 18 and 21), upper cortical layer
neurons (clusters 0, 1, 2, and 17), and dopaminergic neu-
rons (cluster 15). For both genotypes, PITRM1+/+ and
PITRM1−/−, all clusters were similarly represented, with
60% of the identified single cells expressing neuronal
lineage markers and almost 20% expressing glial cell mar-
kers (Fig. 3c, d). To identify cell-type-specific mechanistic
Fig. 1 PITRM1−/− iPSC-derived neurons show the induction of
UPRmt and enhanced mitophagy. Control PITRM1+/+ (WT) and
isogenic PITRM1−/− (KO) iPSCs were differentiated into cortical
neurons. a Immunostaining of indicated differentiated iPSC cultures at
DIV 35. Cells were stained for TBR1 (green) and β-III-tubulin
(β-TUBIII, red). Nuclei were counterstained with DAPI (blue). Scale
bar,50 μm. b Quantification of β-TUBIII/DAPI and TBR1/β-TUBIII-
positive cells in differentiated iPSC cultures at DIV 35 (mean+ SEM;
n= 3). c Isogenic PITRM1+/+ and PITRM1−/− iPSC-derived neurons
were stained with tetramethylrhodamine methylester (TMRM) and
MitoTracker Green (MGreen) fluorescent dyes to determine mito-
chondrial membrane potential and mitochondrial mass, respectively.
Representative images are shown. Scale bar, 10 μm. d Mitochondrial
membrane potential (TMRM fluorescence) in neuronal soma and
neurites (mean+ SEM; *p < 0.05, two-tailed t test, n= 3). e Gene
expression levels of mitochondrial stress response genes in
PITRM1+/+ and PITRM1−/− iPSC-derived cortical neurons (mean+
SEM; *p < 0.05, **p < 0.01, ***p < 0.001, two-tailed t test, n= 5).
f, g Representative western blots of the mitochondrial chaperones
HSPA9 and HSP60 and the mitochondrial protease LONP1 in
PITRM1+/+ and PITRM1−/− iPSC-derived cortical neurons. Quanti-
fication of protein levels relative to the loading control is shown in
(g) (mean+ SEM; *p < 0.05, two-tailed t test, n= 3). h Western blot
analysis for LC3 in PITRM1+/+ and PITRM1−/− iPSC-derived neu-
ronal cultures, untreated (−) or treated with 200 μM leupeptin and
20 mM NH4Cl for 4 h (+). i Quantification of LC3 flux normalized to
WT (mean+ SEM; *p < 0.05, two-tailed t test, n= 3). j Representa-
tive western blot of isolated mitochondria from PITRM1+/+ and
PITRM1−/− iPSC-derived neurons probed against ubiquitin and
VDAC as the loading control. k Quantification of mitochondrial
protein ubiquitination levels in PITRM1+/+ and PITRM1−/− iPSC-
derived neurons (mean+ SEM; **p < 0.01, two-tailed t test, n= 3).
I mtDNA content was measured as the mitochondrial (16S) to nuclear
(RPLP0) DNA ratio by qRT-PCR (mean+ SEM; *p < 0.05, two-tailed
t test, n= 3).
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pathways associated with DEG sets between isogenic
PITRM1+/+ and PITRM1−/− cerebral organoids, we per-
formed pathway analysis in the different clusters. Canonical
pathway analysis revealed that mitochondrial function,
oxidative phosphorylation, and the sirtuin pathway were
common dysregulated pathways among neurons (cluster 1),
glial cells (cluster 3), astrocytes (cluster 13), and microglia
(cluster 22) (Fig. 3e and Supplementary Table 2). Interest-
ingly, synaptogenesis and long-term potentiation emerged
as differentially dysregulated pathways in neurons, whereas
inflammatory pathways (including iNOS, PPAR signaling
TNFR1, RAR activation, chemokine, and IL-17A signaling
pathways) were significantly dysregulated in astrocytes. In
line with an impact of PITRM1 deficiency on immune
pathways, we found a significant increase of the inflam-
matory cytokine TNF-α in PITRM1−/− cerebral organoids
(Supplementary Fig. 3d). In addition, we found a non-
significant increase in IL-1β levels (Supplementary Fig. 3d).
PITRM1−/− cerebral organoids exhibit the main
features of AD pathology and the induction of
mitochondrial stress response
Next, we examined whether PITRM1−/− cerebral organoids
develop AD-like neurodegenerative features. Western blotting
revealed increased APP levels in 2-month-old PITRM1−/−
cerebral organoids (Fig. 4a, b). Furthermore, immunoassay
measurements showed a higher Aβ40, Aβ42, and Aβ42/Aβ40
ratio in PITRM1−/− cerebral organoids compared with con-
trols (Fig. 4c). Western blot analysis revealed tau hyper-
phosphorylation in 2-month-old PITRM1−/− cerebral
organoids compared with PITRM1+/+ organoids (Fig. 4d,
e). Similarly, immunofluorescence staining confirmed
increased APP and phospho-tau levels in PITRM1−/−
organoids compared with PITRM1−/− controls starting at
2 months (Supplementary Fig. 4a, b). No further increase of
tau hyperphosphorylation was observed at later time points
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Fig. 2 PITRM1−/− iPSC-derived neurons show the accumulation
of APP and increased levels of Aβ peptides. a Representative wes-
tern blots of APP in PITRM1+/+ and PITRM1−/− iPSC-derived cor-
tical neurons. b Quantification of APP levels normalized to the loading
control (mean+ SEM; **p < 0.01, two-tailed t test, n= 5). c Quanti-
fication of Aβ species and the Aβ42/Aβ40 ratio in the supernatant of
PITRM1+/+ and PITRM1−/− iPSC-derived cortical neurons at DIV 35,
as performed by Meso Scale immunoassay (mean+ SEM; *p < 0.05,
***p < 0.001, two-tailed t test, n= 5). d Gene expression levels of
APP in PITRM1+/+ and PITRM1−/− iPSC-derived cortical neurons
(mean+ SEM; ***p < 0.001, two-tailed t test, n= 5). e Representative
western blot of PITRM1+/+ and PITRM1−/− iPSC-derived neurons of
total ubiquitinated protein levels. f Quantification of the protein ubi-
quitination level in PITRM1+/+ and PITRM1−/− iPSC-derived neu-
rons (mean+ SEM; **p < 0.01, two-tailed t test, n= 6).
M. J. Pérez et al.
(Supplementary Fig. 4c). Next, we stained 1-, 2-, and 6-
month-old PITRM1+/+ and PITRM1−/− cerebral organoids,
for cleaved caspase-3. The number of cleaved caspase-3-
positive cells in the neuroepithelial layers was higher in
PITRM1−/− cerebral organoids than in the controls, starting
at 2 months (Fig. 4f, g), suggesting a higher extent of cell
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death. No further increase in cell death was observed at later
time points (Supplementary Fig. 4d). BTA-1 and thioflavin-
T-positive aggregates were detected in cerebral organoids
generated from PITRM1−/− iPSCs, indicating that protein
deposits are organized into amyloid-like aggregates, similar
to those observed in AD plaques (Fig. 4h, i and Supple-
mentary Fig. 4e, f). To analyze ubiquitin-dependent protein
turnover, an immunostaining against ubiquitinated proteins
was performed. PITRM1−/− organoids display increased
levels of ubiquitinated proteins (Fig. 4j, k). Next, we
examined the expression levels of genes involved in UPRmt
in 2-month-old PITRM1+/+ and PITRM1−/− cerebral
organoids. PITRM1−/− cerebral organoids exhibited a sig-
nificant induction of UPRmt transcripts (ATF4, DDIT3,
HSP60, HSPA9, ERO1) (Fig. 4l). Moreover, gene expres-
sion of the mitochondrial proteases, LONP1 and CLPP, was
significantly upregulated in PITRM1−/− cerebral organoids
compared with controls (Fig. 4l).
Inhibition of UPRmt exacerbates Aβ proteotoxicity
Given that UPRmt can extend the lifespan in a variety of
organisms [28–31], we asked whether the induction of
UPRmt observed in PITRM1−/− cerebral organoids could act
as a protective mechanism against defects of mitochondrial
protein maturation and Aβ proteotoxicity. To this end, cer-
ebral organoids were treated daily with ISRIB, a global ISR
inhibitor [21, 32]. First, we examined APP levels and the
phospho-tau/tau ratio by immunostaining. Consistent with
the protective role of UPRmt in our model, ISRIB-treated
cerebral organoids showed higher APP and phospho-tau
levels compared with controls (Fig. 5a–c). In parallel, ISRIB
treatment significantly increased the Aβ42/Aβ40 ratio
(Fig. 5d) in both PITRM1+/+ and PITRM1−/− organoids. In
line with these findings, ISRIB-treated PITRM1+/+ cerebral
organoids show a significant increase in cleaved caspase-3-
positive cells (Fig. 5e). Interestingly, ISRIB-treated cerebral
organoids also showed an increase of mitochondrial DNA,
suggesting that the inhibition of UPRmt leads to a decrease in
mitochondrial clearance (Fig. 5f).
Enhancing mitophagy via NAD+ precursors
ameliorates Aβ proteotoxicity
Because defects in mitophagy have been shown to con-
tribute to AD [33], and ISRIB-treated cerebral organoids
showed decreased mitochondrial clearance and the exacer-
bation of AD-like phenotypes, we investigated whether
enhancing mitochondrial clearance ameliorates the AD-like
phenotype in PITRM1-related mitochondrial neurodegen-
eration. To this end, PITRM1+/+ and PITRM1−/− cerebral
organoids were treated with the NAD+ precursor NMN,
which has been shown to ameliorate mitochondrial function
and clearance [34, 35]. While NMN supplementation
resulted in an increased mtDNA/nDNA ratio in PITRM1+/+
organoids, a significant decrease in mitochondrial content
was observed in PITRM1−/− organoids after treatment
(Fig. 5g). These data suggest a differential role of NAD+
boosters under physiological and pathological conditions—
namely, the induction of mitochondrial biogenesis or the
enhancement of mitochondrial clearance, respectively.
Furthermore, NMN treatment significantly decreased the
Aβ42/Aβ40 and phospho-tau/total tau ratios in PITRM1−/−
cerebral organoids as revealed by Meso Scale and ELISA
measurements (Fig. 5h, i). Importantly, NMN treatment
significantly decreased the number of cleaved caspase-3-
positive cells in PITRM1−/− cerebral organoids (Fig. 5j).
Discussion
Because the brain is the organ with the highest energy
demand, it comes as no surprise that it also represents the
major disease target, both in genetically driven primary
mitochondrial diseases as well as in common age-related
neurodegenerative disorders. Despite this evidence, the
causal link between mitochondrial demise and neurode-
generation remains elusive. We have recently reported that
pathogenic variants in the nuclear-encoded mitochondrial
peptidase PITRM1 result in childhood-onset recessive cer-
ebellar disease characterized by spinocerebellar ataxia, mild
intellectual disability, psychiatric manifestations, and cog-
nitive decline [2, 3]. The clinical picture of these patients is
unusual for mitochondrial disease, with a very slow pro-
gression of cognitive and psychiatric symptoms from
childhood to their late sixties [2].
PITRM1+/− mice show a neurological phenotype with
the presence of Aβ-positive plaques in the neuropilum [2].
However, due to the embryonic lethality of complete
PITRM1−/− [2], the exact mechanisms of PITRM1 in brain
function and disease could not be completely studied. To
address these questions, we have generated a novel human
stem-cell-based model of the loss of PITRM1 function
that recapitulates several pathological aspects of human
Fig. 3 scRNA-seq of cerebral organoids reveals a cell-type-specific
impact of PITRM1. a Generation and characterization of cerebral
organoids from PITRM1+/+ and PITRM1−/− iPSCs. Immunostaining for
β-TUBIII (green), TBR1 (red), and CTIP2 (red) of 2-month-old cerebral
organoids. Cell nuclei were counterstained with DAPI (blue). Scale bar,
100 µm. b UMAP dimensionality reduction plot showing the unsu-
pervised clustering of PITRM1+/+ and PITRM1−/− cerebral organoids.
Total n= 15,183 cells. c Pie charts showing the frequency of major cell
clusters across the genotypes. Cell clusters were determined by expres-
sion of specific markers. d UMAP dimensionality reduction plot showing
five distinguished clusters with cell-type identities as determined by the
expression of specific markers. e Ingenuity pathway analysis (IPA) of
DEG in neurons (cluster 1), progenitor cells (cluster 24), glial cells
(cluster 3), astrocytes (cluster 13), and microglia (cluster 22).
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PITRM1-related mitochondrial and adult-onset neurode-
generative diseases. Employing iPSC-derived cortical neu-
rons, we found that the loss of PITRM1 function leads to a
strong induction of mitochondrial stress responses,
enhanced autophagic flux and mitochondrial clearance,
increased levels of APP and Aβ peptides, and an increased
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Aβ42/40 ratio. Several works have shown the uptake and
accumulation of Aβ within the mitochondria in the post-
mortem brains of AD patients as well as in later stages of
disease in APP transgenic mice [36, 37]. Furthermore,
in vitro and yeast-based modeling has shown that the loss of
PITRM1 function results in the incomplete degradation of
Aβ in the mitochondria [2, 9]. Using sub-fractionation
methods coupled with a highly sensitive immunoassay, we
were unable to detect Aβ peptides in mitochondrial extracts
from PITRM1-deficient cortical neurons. We cannot
exclude the accumulation of a low amount of Aβ peptides
within the mitochondria, below the detection limit of this
study. We found that PITRM1−/− neurons exhibit a sig-
nificant decrease in mitochondrial membrane potential.
However, PITRM1−/− neurons did not show an increase in
mitochondrial ROS production or defects in oxidative
phosphorylation, which have been shown to be a direct
effect of the accumulation of Aβ within mitochondria
[38, 39]. Interestingly, the reduction of mitochondrial
membrane potential was more evident in the neurites
compared with the soma. Based on these results, we
hypothesize that the mitochondrial pool in the neurites is the
one which is most affected during the early stages of the
diseases. Such localized changes may prevent the detection
of significant changes in overall mitochondrial respiration.
Our data suggest that the imbalance of mitochondrial
proteostasis can be the first event in the pathogenetic cas-
cade in PITRM1-related neurological syndrome. APP
accumulation observed in PITRM1−/− neurons and cerebral
organoids may be a consequence of the overload of the
proteasome in response to mitochondrial protein misfold-
ing. The ubiquitin–proteasome system (UPS) is also
involved in the quality control of mitochondrial proteins,
especially mitochondrial precursor proteins and proteins of
the outer membrane [40]. Supporting an overload of the
UPS system, we detected an accumulation of ubiquitinated
proteins in PITRM1-deficient neurons and cerebral orga-
noids. Based on these data, we propose that mitochondrial
proteotoxic stress, possibly linked to the accumulation of
non-degraded MTS as a result of PITRM1 dysfunction and
the accumulation of unprocessed mitochondrial proteins,
triggers a cytosolic response with overload and saturation of
the proteasome and defects in cytosolic protein degradation.
PITRM1 deficiency led to a strong induction of UPRmt in
both 2D and brain-organoid model systems. UPRmt is a
transcriptional response involving mitochondrial chaperones
and proteases activated by mitochondrial dysfunction and
defects in mitochondrial protein folding [41]. It is a key
cellular quality control mechanism that promotes the main-
tenance of mitochondrial health and ensures proper cellular
functions [42]. Despite the evidence of UPRmt activation in
the aging and diseased brain [20], whether and how UPRmt
contributes to neurodegenerative processes is unclear.
UPRmt has been proposed as being a double-edged sword,
with its chronic activation leading to detrimental con-
sequences for cellular and organismal function [22, 43]. A
detrimental role of UPRmt has been demonstrated in animal
models of mitochondrial diseases [22, 43]. However, mito-
chondrial stress responses have been documented in AD and
recent work has shown that enhancing UPRmt provides
protections against Aβ proteotoxicity [21, 44]. In line with a
beneficial role of UPRmt, PITRM1−/− cerebral organoids
treated with ISRIB, an inhibitor of the ISR, showed a sig-
nificant increase of APP levels, an increased Aβ42/Aβ40
ratio, tau hyperphosphorylation and cell death. Based on
these data, we propose that PITRM1-related induction of
UPRmt is a protective mechanism against proteotoxic stress
at both the mitochondrial and cytosolic levels. Importantly,
our findings indicate that the consequences of chronic mtISR
upregulation may vary substantially among different mito-
chondrial diseases and that the underlying molecular defect
should be carefully considered for therapeutic decisions.
Though UPRmt was activated in both 2D and 3D
PITRM1 KO models, only PITRM1 KO cerebral organoids
displayed the typical abnormalities observed in the brains of
AD patients, including neuronal cell death, tau pathology,
and the accumulation of protein aggregates, similar to Aβ
plaques. On the other hand, despite APP accumulation and
Fig. 4 PITRM1−/− cerebral organoids display the main patholo-
gical features of AD pathology and the induction of the mito-
chondrial stress response. a Western blot of APP in 2-month-old
PITRM1+/+ and PITRM1−/− cerebral organoids. b Quantification of
APP protein levels in cerebral organoids (mean+ SEM; *p < 0.05,
two-tailed t test, n= 5). c Quantification of Aβ species in the super-
natant of PITRM1+/+ and PITRM1−/− iPSC-derived cerebral orga-
noids, as performed by Meso Scale immunoassay (mean+ SEM; *p <
0.05, **p < 0.01, ***p < 0.0001, two-tailed t test, n= 7). d Repre-
sentative western blots of phospho-tau (Thr231, Ser202 and Thr205,
Thr181 phosphorylation sites) and total tau in PITRM1+/+ and
PITRM1−/− cerebral organoids; total tau and β-Actin were used as the
loading controls. e Quantification of phospho-tau protein levels in
cerebral organoids relative to the loading control total tau/β-Actin
(mean+ SEM; *p < 0.05, two-tailed t test, n= 3–5). f Immunostaining
for β-TUBIII (green) and cleaved caspase-3 (cCASP3, red) in
PITRM1+/+ and PITRM1−/− 2-month-old cerebral organoids. Cell
nuclei were counterstained with DAPI (blue). Scale bar, 100 µm.
g Analysis of the ratio of cCASP3-positive cells relative to the total
number of β-TUBIII/DAPI cells in 2-month-old cerebral organoids
(mean+ SEM; ***p < 0.001, two-tailed t test, n= 3). h Phalloidin
(red) and BTA-1 (blue) staining in cerebral organoids. Representative
confocal images are shown. Scale bars, 100 μm. i Quantification of the
size of BTA-1-positive areas in cerebral organoids (mean+ SEM;
**p < 0.01, two-tailed t test, n= 3). j MAP2 (green) and ubiquitin
(red) immunostaining in cerebral organoids. Representative confocal
images are shown. Cell nuclei were counterstained with DAPI (blue).
Scale bars, 100 μm. k Quantification of ubiquitin mean fluorescent
intensity (mean+ SEM; *p < 0.05, two-tailed t test, n= 3). l Gene
expression levels of mitochondrial stress response genes in
PITRM1+/+ and PITRM1−/− cerebral organoids (mean+ SEM; *p <
0.05, **p < 0.01, ***p < 0.001, two-tailed t test, n= 4–6).
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an increased Aβ42/Aβ40 ratio, we did not detect overt cell
death, nor did we detect Aβ aggregates or tau pathology in
2D iPSC-derived neuronal cultures. These findings indicate
that 3D systems, as compared with 2D systems, provide a
more relevant disease model that is advantageous in
investigating the link between cellular proteostasis and
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disease. Due to the prolonged culturing conditions, as well
as the presence and interaction among different cell types,
including glial cells, 3D model systems may promote the
development of disease-relevant phenotypes such as protein
aggregation and neuronal death [45]. Combining cerebral
organoids with scRNA-seq, we were able to demonstrate
the cell-type-specific impact of the loss of PITRM1 func-
tion. PITRM1 has a strong impact on pathways related to
mitochondrial function (oxidative phosphorylation, mito-
chondrial dysfunction, sirtuin signaling, and the NRF2-
mediated oxidative stress response). Interestingly, this effect
was observed in all the major brain cell types except for
progenitor cells. In line with a role for immune pathways in
AD pathology, astrocyte signatures also markedly differed
between PITRM1+/+ and PITRM1−/− cerebral organoids
with significant dysregulation of immune-related pathways.
These data highlight mitochondrial dysfunction as an
important driver of immune reactions. Though microglia
emerged in our scRNA sequencing analysis and previous
reports show the development of microglia within cerebral
organoids [46], the low number of cells identified may have
hampered the identification of microglial relevant pathways
in our primary mitochondrial disease organoid model.
With respect to the mechanisms, our data suggest that
PITRM1 deficiency triggers compensatory quality control
mechanisms at both the cytosolic and mitochondrial levels
(i.e., the induction of UPRmt and autophagy/mitophagy) that
ensure the maintenance of cellular proteostasis. However,
over time, these mechanisms may not be sufficient to pro-
tect neuronal cells against mitochondrial proteotoxicity or
may overload cytosolic quality control pathways, such as
the UPS, as observed in long-term culture cerebral
organoids.
Several findings—including the induction of autophagic
flux, decreased mtDNA levels, and an increase of mito-
chondrial protein ubiquitination—suggest that PITRM1
deficiency leads to increased mitochondrial clearance. It is
known that defects in PITRM1 activity lead to impaired
MTS processing and the accumulation of MTS and pre-
cursor proteins that have a toxic effect on mitochondria. In
line with this evidence, we report that PITRM1−/− neurons
show defects in the maturation of the human frataxin pre-
cursor and decreased mitochondrial membrane potential.
Enhanced mitophagy could be triggered by mitochondrial
depolarization in response to MTS accumulation within
mitochondria. Furthermore, UPRmt—and, in general, the
ISR—activates the autophagic pathway [24, 25]. Interest-
ingly, inhibition of ISR resulted in an increase in mtDNA,
suggesting that the activation of UPRmt is linked to the
enhanced mitochondrial clearance in our model.
Mitochondrial stress response and mitophagy transcripts
have been found to be upregulated in mild cognitive
impairment as well as in mild and moderate AD patients,
whereas defective mitophagy may play a role in the disease
progression at later stages [33, 47]. Fang et al. have recently
shown that the enhancement of mitophagy is able to rescue
AD-related pathology in different AD model systems [33].
In line with this finding, we show that stimulating mito-
phagy with NMN, an NAD+ booster, significantly
improves mitochondrial clearance, with a reduction of the
Aβ42/Aβ40 ratio, tau hyperphosphorylation and neuronal
loss. On the other hand, inhibition of UPRmt with ISRIB led
to decreased mitochondrial clearance and the aggravation of
Aβ and tau pathology. Thus, our data suggest that mito-
phagy has a protective role against mitochondrial proteo-
toxicity induced by PITRM1 deficiency. Interestingly,
NMN-related induction of mitophagy was evident only in
PITRM1−/− cerebral organoids, while induction of mito-
chondrial biogenesis was detected in PITRM1+/+organoids
upon treatment.
In conclusion, we report a novel cellular model of human
PITRM1 deficiency that recapitulates several fundamental
pathological aspects of PITRM1-related mitochondrial dis-
ease. Using human iPSC-derived cortical neurons and
Fig. 5 UPRmt and mitophagy exert a protective role in PITRM1−/−
cerebral organoids. PITRM1+/+ and PITRM1−/− cerebral organoids
were treated with 500 nM ISRIB or vehicle, daily, from DIV 20 to
DIV 50. a, b MAP2 (green), APP (red, in a), and phospho-tau (p-tau;
red, in b) immunostaining in PITRM1+/+ and PITRM1−/− cerebral
organoids treated with ISRIB or vehicle. Representative confocal
images are shown. Cell nuclei were counterstained with DAPI (blue).
Scale bars, 100 μm. c Quantification of APP and phospho-tau mean
fluorescent intensity (mean+ SEM; *p < 0.05, **p < 0.01, ***p <
0.001, two-tailed t test, n= 3–4). d Quantification of Aβ species in the
supernatant of PITRM1+/+ and PITRM1−/− cerebral organoids treated
with ISRIB or vehicle, as measured by Meso Scale immunoassay
(mean+ SEM; *p < 0.05, ***p < 0.001, two-tailed t test, n= 6–7).
e Immunostaining for β-TUBIII (green) and cleaved caspase-3
(cCASP3, red) in PITRM1+/+ and PITRM1−/− cerebral organoids
treated with ISRIB or vehicle. Cell nuclei were counterstained with
DAPI (blue). Scale bar, 100 µm. Quantification of the ratio of
cCASP3-positive cells relative to the total number of β-TUBIII/DAPI
cells is shown (mean+ SEM; **p < 0.01, two-tailed t test, n= 3–4).
f mtDNA content was measured in PITRM1+/+ and PITRM1−/− cer-
ebral organoids treated with ISRIB or vehicle as the mitochondrial
(16S) to nuclear (RPLP0) DNA ratio by qRT-PCR (mean+ SEM;
*p < 0.05, two-tailed t test, n= 4). g–j PITRM1+/+ and PITRM1−/−
cerebral organoids were treated with 500 μM NMN or vehicle, daily,
from DIV 45 to DIV 50. g mtDNA content was measured as the
mitochondrial (16S) to nuclear (RPLP0) DNA ratio by qRT-PCR
(mean+ SEM; **p < 0.01, ***p < 0.0001, two-tailed t test, n= 3).
h Aβ1–42/Aβ1–40 ratio in cerebral organoids measured by Meso
Scale immunoassay (mean+ SEM; **p < 0.01, two-tailed t test, n=
4–7). i ELISA assay measuring the levels of total and phospho-tau
levels in cerebral organoid homogenates. The results are presented as
the ratio of phospho-tau/total-tau (mean+ SEM; ***p < 0.0001, two-
tailed t test, n= 4). j Immunostaining and quantification for β-TUBIII
(green) and cleaved caspase-3 (cCASP3, red) in PITRM1−/− cerebral
organoids treated with NMN or vehicle. Cell nuclei were counter-
stained with DAPI (blue). Scale bar, 100 µm. Analysis of the ratio of
cCASP3-positive cells relative to the total number of β-TUBIII/DAPI
cells is shown (mean+ SEM; **p < 0.01, two-tailed t test, n= 4).
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cerebral organoids, we show that the loss of PITRM1
function leads to pathological features similar to those
observed in AD—namely, protein aggregation, tau hyper-
phosphorylation, and neuronal death. We report that
PITRM1 deficiency induces the impairment of mitochon-
drial proteostasis and the activation of UPRmt, which acti-
vates cytosolic quality control pathways such as the UPS
and autophagy. The overload of the UPS causes, in the long
run, a reduced capacity of degrading cytosolic proteins
leading to APP accumulation, an increased level of Aβ
species, an increased Aβ42/40 ratio, and extracellular protein
aggregation. Furthermore, we show that, similar to what has
been described in AD, enhancing UPRmt and mitophagy
ameliorates neuropathological features in primary mito-
chondrial disease-related neurodegeneration. Importantly,
although human PITRM1 mutations are relatively rare, the
disease mechanisms described in the present study may
apply to both primary mitochondrial diseases and more
common adult-onset neurological diseases. Thus, our data
support a mechanistic link between primary mitochondrial
disorders and common neurodegenerative proteinopathies.
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